ASHP is a leader in establishing and promoting guidelines for the safe and appropriate use of medications in hospitals and health-systems. In addition, the organization has long advocated for increased authorities and funding for the FDA to conduct post-marketing surveillance activities. Increased incidences of drug safety problems and medication errors have raised the public’s awareness about these important issues. Recent reports by the Institute of Medicine and the Government Accountability Office have also elevated their rank on the federal policy agenda. As Congress examines these issues during the 110th Congress, ASHP will promote safe practices, as well as increased oversight and funding for the Food and Drug Administration (FDA) so it may carry out its mission to protect the public’s health.
ASHP Speaks Out
Restricted Drug Distribution System (RDDS)
Post-Marketing Surveillance
Medication Error Prevention
Compounding
ASHP Policies, Positions and Guidelines
References
Post-Marketing Surveillance
Legislation
Reports
Medication Error Prevention
Compounding